1 minute read
Reference
www.aasraw.com of Sunitinib Malate powder, their production was controlled strictly under cGMP condition, the quality can be tracked at any time and they may provided all testing reports when you order it. As for the Sunitinib Malate powder costs/price, it should be reasonable, in my eyes. Because I have got many prices from different Sunitinib Malate suppliers, compared with quality, I think aasraw will be not bad choice.
[1] Food and Drug Administration. Sunitinib (Sutent) Prescribing information. 2015.
Advertisement
[2] C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions, ” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981.
[3] Z. Ansari and M. K. George, “Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report, ” Journal of Medical Case Reports, vol. 7, article 54, 2013.
[4] K. Sakai, K. Komai, D. Yanase, and M. Yamada, “Plasma VEGF as a marker for the diagnosis and treatment of vasculitic neuropathy, ” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 2, article 296, 2005.
[5] European Medicines Agency. Sunitinib (SUTENT). Summary of Product Characteristics. 2015.
[6] Pajares B, Torres E, Trigo JM et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol 2012; 14: 94-101.
11
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com
[7] Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015; 79: 241-253.
[8] Jamie Dlugosch (2009-03-13). “Will biologics and Sutent save Pfizer?” . InvestorPlace.
[9] BMJ 31-Jan-2009 “NICE and the challenge of cancer drugs” p271
[10] Blay JY, Reichardt P (June 2009). “Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations” . Expert Rev Anticancer Ther. 9 (6): 831–8. doi:10.1586/era.09.34. PMID 19496720. S2CID 23601578.
12
